Search Within

Eric E Hedrick

Formats
  1. Meeting Abstract (10)
  2. Journal Article (6)
Groups
  1. Department of Medicine (15)
  2. Hematologic Malignancies, Division of (15)
  3. Center for Hematologic Malignancies (13)
  4. Lymphoma (13)
  5. Radiation Oncology, Department of (8)
  6. Survivorship Research (8)

More Groups

People
  1. Craig Moskowitz (15)
  2. Andrew Zelenetz (13)
  3. Stephen Nimer (12)
  4. Joachim Yahalom (8)
  5. David Straus (6)
  6. Ariela Noy (5)

More People

Years
  1. 2003 (1)
  2. 2001 (3)
  3. 2000 (4)
  4. 1999 (4)
  5. 1998 (2)
  6. 1997 (1)

More Years

Publications
  1. Blood (12)
  2. Cancer (1)
  3. Journal of Clinical Oncology (1)
  4. Leukemia (1)
  5. Leukemia and Lymphoma (1)
Publishers
  1. American Society of Hematology (12)
  2. American Society of Clinical Oncology (1)
  3. Nature Publishing Group (1)
  4. Taylor & Francis Group (1)
  5. Wiley Blackwell (1)

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma
    Journal Article

    Wang, E. S.; Straus, D. J.; Teruya-Feldstein, J.; Qin, J.; Portlock, C.; Moskowitz, C.; Goy, A.; Hedrick, E.; Zelenetz, A. D.; Noy, A.
    Cancer (2003)

    Fulltext@MSK | Save
  • Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)
    Meeting Abstract

    Kewalramani, T.; Zelenetz, A.; Bertino, J.; Donnelly, G.; Hedrick, E.; Noy, A.; O'connor, O.; Portlock, C.; Straus, D.; Yahalom, J.; more...
    Blood (2001)

    Fulltext@MSK | Save
  • Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma
    Journal Article

    Cohen, B. J.; Moskowitz, C.; Straus, D.; Noy, A.; Hedrick, E.; Zelenetz, A.
    Leukemia and Lymphoma (2001)

    Fulltext@MSK | Save
  • A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model
    Journal Article

    Moskowitz, C. H.; Nimer, S. D.; Zelenetz, A. D.; Trippett, T.; Hedrick, E. E.; Filippa, D. A.; Louie, D.; Gonzales, M.; Walits, J.; Coady-Lyons, N.; more...
    Blood (2001)

    Fulltext@MSK | Save
  • The outcome of patients with primary refractory Hodgkin's disease (HD) treated with high dose chemoradiotherapy and ASCT
    Meeting Abstract

    Moskowitz, C. H.; Nimer, S. D.; Zelenetz, A. D.; Hedrick, E. E.; Gonzalez, M.; Yahalom, J.
    Blood (2000)

    Fulltext@MSK | Save
  • Outcome of adult patients (pts) with chemosensitive (CS) relapsed or primary refractory Hodgkin's disease (HD) or aggressive NHL (NHL) after failure of autologous transplantation (ASCT)
    Meeting Abstract

    Kewalramani, T.; Hedrick, E. E.; Malhotra, S.; Qin, J.; Yahalom, J.; Zelenetz, A. D.; Nimer, S. D.; Moskowitz, C. H.
    Blood (2000)

    Fulltext@MSK | Save
  • Baseline circulating CD34+ cell counts predict leukapheresis yield in a diverse transplant population
    Meeting Abstract

    Comenzo, R. L.; Reich, L.; Moskowitz, C.; Hedrick, E.; Childs, B. H.; Kushner, B.; Nimer, S. D.; Wuest, D.
    Blood (2000)

    Fulltext@MSK | Save
  • High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: An intention-to-treat analysis
    Journal Article

    Kewalramani, T.; Zelenetz, A. D.; Hedrick, E. E.; Donnelly, G. B.; Hunte, S.; Priovolos, A. C.; Qin, J.; Lyons, N. C.; Yahalom, J.; Nimer, S. D.; more...
    Blood (2000)

    Fulltext@MSK | Save
  • Factors predicting outcome in patients with primary refractory intermediate grade lymphoma (IGL) eligible for high dose chemoradiotherapy (HDT) and autologous stem cell transplant (ASCT)
    Meeting Abstract

    Kewalramani, T.; Hedrick, E. E.; Donnelly, G. B.; Satagopan, J. M.; Hunte, S.; Priovolos, A.; Zelenetz, A. D.; Nimer, S. D.; Moskowitz, C. H.
    Blood (1999)

    Fulltext@MSK | Save
  • Persistent gallium avidity after second-line chemotherapy in Hodgkin's disease (HD) and intermediate-grade non-hodgkin's lymphoma (IGL) does not predict outcome following autologous stem cell transplantation (ASCT)
    Meeting Abstract

    Donnelly, G. B.; Hedrick, E. E.; Kewalramani, T.; Satagopan, J. M.; Walits, J.; Yahalom, J.; Zelenetz, A. D.; Nimer, S. D.; Moskowitz, C. H.
    Blood (1999)

    Fulltext@MSK | Save